MA28481B1 - Dérivés d'imidazole pour le traitement de troubles neurodégénératifs - Google Patents

Dérivés d'imidazole pour le traitement de troubles neurodégénératifs

Info

Publication number
MA28481B1
MA28481B1 MA29336A MA29336A MA28481B1 MA 28481 B1 MA28481 B1 MA 28481B1 MA 29336 A MA29336 A MA 29336A MA 29336 A MA29336 A MA 29336A MA 28481 B1 MA28481 B1 MA 28481B1
Authority
MA
Morocco
Prior art keywords
treatment
neurodegenerative disorders
imidazole derivatives
imidazole
derivatives
Prior art date
Application number
MA29336A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Karen Jean Coffman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28481B1 publication Critical patent/MA28481B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29336A 2004-03-23 2006-09-22 Dérivés d'imidazole pour le traitement de troubles neurodégénératifs MA28481B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55562304P 2004-03-23 2004-03-23

Publications (1)

Publication Number Publication Date
MA28481B1 true MA28481B1 (fr) 2007-03-01

Family

ID=34961257

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29336A MA28481B1 (fr) 2004-03-23 2006-09-22 Dérivés d'imidazole pour le traitement de troubles neurodégénératifs

Country Status (42)

Country Link
US (3) US7342118B2 (fr)
EP (1) EP1730119B1 (fr)
JP (2) JP4054845B2 (fr)
KR (1) KR100814599B1 (fr)
CN (1) CN1934091B (fr)
AP (1) AP2379A (fr)
AR (1) AR049875A1 (fr)
AT (1) ATE399155T1 (fr)
AU (1) AU2005225635B2 (fr)
BR (1) BRPI0509069B8 (fr)
CA (1) CA2560580C (fr)
CR (1) CR8644A (fr)
CY (1) CY1108347T1 (fr)
DE (1) DE602005007717D1 (fr)
DK (1) DK1730119T3 (fr)
DO (1) DOP2005000040A (fr)
EA (1) EA011689B1 (fr)
EC (1) ECSP066879A (fr)
ES (1) ES2308441T3 (fr)
GE (1) GEP20084420B (fr)
GT (1) GT200500060A (fr)
HN (1) HN2005000115A (fr)
HR (1) HRP20080375T3 (fr)
IL (1) IL177594A0 (fr)
IS (1) IS8550A (fr)
MA (1) MA28481B1 (fr)
NL (1) NL1028598C2 (fr)
NO (1) NO338263B1 (fr)
NZ (1) NZ549331A (fr)
PA (1) PA8627201A1 (fr)
PE (1) PE20051155A1 (fr)
PL (1) PL1730119T3 (fr)
PT (1) PT1730119E (fr)
RS (1) RS50595B (fr)
SI (1) SI1730119T1 (fr)
SV (1) SV2006002055A (fr)
TN (1) TNSN06300A1 (fr)
TW (1) TWI372146B (fr)
UA (1) UA83899C2 (fr)
UY (1) UY28817A1 (fr)
WO (1) WO2005092864A1 (fr)
ZA (1) ZA200606957B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
EP1940802A2 (fr) 2005-09-22 2008-07-09 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
DE102006048042A1 (de) * 2006-10-11 2008-04-17 Bayer Healthcare Ag Acylaminoimidazole und Acylaminothiazole
US8779002B2 (en) * 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
WO2009093463A1 (fr) * 2008-01-23 2009-07-30 Taiho Pharmaceutical Co., Ltd. Inhibiteur de la mort cellulaire neuronale
EP2398771B1 (fr) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Composés hétérocycliques qui modulent le récepteur cb2
WO2010100606A1 (fr) * 2009-03-03 2010-09-10 Pfizer Inc. Nouveaux phényl imidazoles et phényl triazoles en tant que modulateurs de la gamma sécrétase
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
WO2012012307A1 (fr) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Composés sulfonylés qui modulent le récepteur cb2
RU2465273C2 (ru) * 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
WO2015092614A1 (fr) 2013-12-20 2015-06-25 Pfizer Inc. Altérations d'activation de notch dans le cancer du sein
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CA2990564A1 (fr) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Derive d'amide heterocyclique bicyclique
AU2016284398C1 (en) 2015-06-22 2021-01-07 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
EP3843735A1 (fr) * 2018-08-27 2021-07-07 Universiteit Maastricht Inhibiteurs sélectifs de la gamma-sécrétase préséniline-2
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
KR102772889B1 (ko) * 2019-08-09 2025-02-26 화이자 인코포레이티드 (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도
ES3055762T3 (en) 2019-08-09 2026-02-16 Pfizer Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
KR102782229B1 (ko) * 2019-10-02 2025-03-20 (주)카이노스메드 N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
JP2023524854A (ja) 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用
KR20230069181A (ko) 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
EP4255409A1 (fr) 2020-12-07 2023-10-11 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
MX2024002590A (es) 2021-09-01 2024-03-22 Springworks Therapeutics Inc Sintesis de nirogacestat.
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
WO2023079132A1 (fr) 2021-11-08 2023-05-11 Cellestia Biotech Ag Combinaisons pharmaceutiques pour le traitement du cancer
EP4436958A1 (fr) * 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Formes à l'état solide de sels de nirogacestat
EP4223292A1 (fr) 2022-02-07 2023-08-09 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
WO2023174390A1 (fr) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 Forme cristalline de dihydrobromure de nirogacestat, son procédé de préparation et son utilisation
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12667555B2 (en) 2022-05-20 2026-06-30 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat
WO2026018210A1 (fr) 2024-07-19 2026-01-22 Assia Chemical Industries Ltd. Formes à l'état solide de sel de dichlorhydrate de nirogacestat
CN119930523B (zh) * 2025-01-22 2026-01-02 上海皓元医药股份有限公司 一种硝加司他中间体的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50314A (en) * 1865-10-03 Improvement in telegraph-cables
US4512A (en) * 1846-05-09 Smut-machine
DE1236426B (de) * 1960-08-25 1967-03-09 Dolomitwerke Gmbh Verfahren zur Wasseraufbereitung
US5401851A (en) 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1289526A4 (fr) 2000-05-30 2005-03-16 Merck & Co Inc Agonistes du recepteur de la melanocortine
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
JP2002059707A (ja) * 2000-08-23 2002-02-26 Bridgestone Corp 空気入りタイヤ及び空気入りタイヤの製造方法
WO2002040445A1 (fr) 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
ES2616539T3 (es) 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
OA12937A (en) 2002-10-09 2006-10-13 Pfizer Prod Inc Thiazole compounds for the treatment of neurodegenerative disorders.
JP2006504725A (ja) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性障害治療用ピラゾール化合物
JP2006182648A (ja) * 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
MXPA05012196A (es) 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
EP1654260A4 (fr) 2003-08-01 2008-09-24 Pfizer Prod Inc Composes heteroaryle a 6 elements pour traiter des troubles neurodegeneratifs
MXPA06001480A (es) 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
US7348968B2 (en) * 2003-12-02 2008-03-25 Sony Corporation Wireless force feedback input device
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en) 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7309709B2 (en) 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1940802A2 (fr) * 2005-09-22 2008-07-09 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques

Also Published As

Publication number Publication date
ES2308441T3 (es) 2008-12-01
WO2005092864A1 (fr) 2005-10-06
AR049875A1 (es) 2006-09-13
BRPI0509069B8 (pt) 2021-05-25
SI1730119T1 (sl) 2008-10-31
CN1934091B (zh) 2012-02-08
DK1730119T3 (da) 2008-08-11
EP1730119B1 (fr) 2008-06-25
AP2006003727A0 (en) 2006-10-31
HK1099756A1 (en) 2007-08-24
US7951958B2 (en) 2011-05-31
AP2379A (en) 2012-03-08
UY28817A1 (es) 2005-10-31
JP2007291123A (ja) 2007-11-08
NZ549331A (en) 2010-08-27
US20080227781A1 (en) 2008-09-18
US20100168107A1 (en) 2010-07-01
TNSN06300A1 (fr) 2007-12-03
EP1730119A1 (fr) 2006-12-13
HRP20080375T3 (hr) 2008-09-30
CN1934091A (zh) 2007-03-21
GEP20084420B (en) 2008-07-10
HN2005000115A (es) 2009-04-20
IL177594A0 (en) 2006-12-10
US7342118B2 (en) 2008-03-11
ZA200606957B (en) 2008-03-26
CA2560580C (fr) 2008-12-23
AU2005225635A1 (en) 2005-10-06
DE602005007717D1 (de) 2008-08-07
TWI372146B (en) 2012-09-11
BRPI0509069B1 (pt) 2019-07-02
AU2005225635B2 (en) 2010-06-24
PT1730119E (pt) 2008-09-02
SV2006002055A (es) 2006-05-09
CR8644A (es) 2006-11-01
CY1108347T1 (el) 2014-02-12
BRPI0509069A (pt) 2007-08-21
CA2560580A1 (fr) 2005-10-06
DOP2005000040A (es) 2005-10-21
KR100814599B1 (ko) 2008-03-17
US20050215610A1 (en) 2005-09-29
PE20051155A1 (es) 2006-01-28
ATE399155T1 (de) 2008-07-15
ECSP066879A (es) 2006-11-24
GT200500060A (es) 2005-10-24
KR20060123651A (ko) 2006-12-01
PA8627201A1 (es) 2005-12-23
RS50595B (sr) 2010-05-07
PL1730119T3 (pl) 2008-10-31
NO20064726L (no) 2006-12-22
US7795447B2 (en) 2010-09-14
IS8550A (is) 2006-10-09
EA011689B1 (ru) 2009-04-28
JP4054845B2 (ja) 2008-03-05
EA200601494A1 (ru) 2007-02-27
NL1028598C2 (nl) 2006-01-03
NO338263B1 (no) 2016-08-08
JP2007530525A (ja) 2007-11-01
NL1028598A1 (nl) 2005-09-26
TW200539875A (en) 2005-12-16
UA83899C2 (uk) 2008-08-26

Similar Documents

Publication Publication Date Title
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
TWI372146B (en) Imidazole compounds for the treatment of neurodegenerative disorders
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
EP1727530A4 (fr) Formulations topiques pour le traitement d'etats dermatologiques
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
EP1670518A4 (fr) Arn interference pour le traitement de troubles a gain de fonction
EP1434801A4 (fr) Traitement pour des troubles du systeme nerveux central
EP1461323A4 (fr) Composes destines au traitement de troubles metaboliques
EP2051967A4 (fr) Dérivés de benzimidazole utilisables pour le traitement des troubles liés au récepteur des vallinoïdes trpv1
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP2120930A4 (fr) Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
EP1758854A4 (fr) Composes pyrrolidin-3-yle utiles en tant qu'inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
EP2307011A4 (fr) Utilisation d'isoindoles pour le traitement de troubles neurocomportementaux
EP1658072A4 (fr) Composes pour le traitement de maladies neurodegeneratives
EP1556085A4 (fr) Composes destines au traitement de troubles metaboliques
EP2328584A4 (fr) Traitement de troubles neurologiques à l'aide d'huperzine
EP1581243A4 (fr) Lactoferrine orale pour le traitement des sepsies